PDF(Pubmed)
Abstract：
Lymphatic filariasis is a neglected tropical disease that affects the lymphatic system of humans. The major etiologic agent is a nematode called Wuchereria bancrofti, but Brugia malayi and Brugia timoriare sometimes encountered as causative agents. Mosquitoes are the vectors while humans the definitive hosts respectively. The burden of the disease is heavier in Nigeria than in other endemic countries in Africa. This occurs with increasing morbidity and mortality at different locations within the country, the World Health Organization recommended treatments for lymphatic filariasis include the use of Albendazole (400mg) twice per year in co-endemic areas with loa loa, Ivermectin (200mcg/kg) in combination with Albendazole (400mg) in areas that are co-endemic with onchocerciasis, ivermectin (200mcg/kg) with diethylcarbamazine citrate (DEC) (6mg/kg) and albendazole (400mg) in areas without onchocerciasis. This paper covered a systematic review, meta-analysis, and scoping review on lymphatic filariasis in the respective geopolitical zones within the country. The literature used was obtained through online search engines including PubMed and Google Scholar with the heading \"lymphatic filariasis in the name of the state\", Nigeria. This review revealed an overall prevalence of 11.18% with regional spread of Northwest (1.59%), North Central and North East, (4.52%), South West (1.26%), and South-South with South East (3.81%) prevalence. The disease has been successfully eliminated in Argungu local government areas (LGAs) of Kebbi State, Plateau, and Nasarawa States respectively. Most clinical manifestations (31.12%) include hydrocele, lymphedema, elephantiasis, hernia, and dermatitis. Night blood samples are appropriate for microfilaria investigation. Sustained MDAs, the right testing methods, early treatment of infected cases, and vector control are useful for the elimination of lymphatic filariasis for morbidity management and disability prevention in the country. Regional control strategies, improved quality monitoring of surveys and intervention programs with proper records of morbidity and disability requiring intervention are important approaches for the timely elimination of the disease in Nigeria.
摘要：
淋巴丝虫病是一种被忽视的热带病，影响人类的淋巴系统。主要的病原体是一种名为Wucherriabancrofti的线虫，但是有时会遇到BrugiaMalayi和BrugiaTimoriois作为病原体。蚊子是媒介，而人类是最终的宿主。尼日利亚的疾病负担比非洲其他流行国家更重。这种情况随着国内不同地点的发病率和死亡率的增加而发生，世界卫生组织推荐的淋巴丝虫病治疗方法包括在与loaloa共同流行的地区每年使用阿苯达唑（400mg）两次，伊维菌素（200mcg/kg）与阿苯达唑（400mg）在与盘尾丝虫病共同流行的地区联合使用，在没有盘尾丝虫病的地区，伊维菌素（200mcg/kg）与柠檬酸二乙基卡巴嗪（DEC）（6mg/kg）和阿苯达唑（400mg）。本文进行了系统的回顾，荟萃分析，以及对该国各自地缘政治地区的淋巴丝虫病进行范围审查。使用的文献是通过包括PubMed和GoogleScholar在内的在线搜索引擎获得的，标题为“以国家名义的淋巴丝虫病”，尼日利亚。这篇综述显示，西北地区的总体患病率为11.18%(1.59%)，中北部和东北部，（4.52%），西南（1.26%），和南南与东南（3.81％）患病率。该疾病已在Kebbi州的Argungu地方政府地区（LGA）成功消除，高原,分别是纳萨拉瓦州。大多数临床表现（31.12%）包括鞘膜积液，淋巴水肿,象皮病,疝气,和皮炎。夜间血液样本适用于微丝菌调查。持续的MDAs,正确的测试方法，感染病例的早期治疗，和病媒控制有助于消除淋巴丝虫病，用于该国的发病率管理和残疾预防。区域控制策略，提高对调查和干预计划的质量监测，并记录需要干预的发病率和残疾，是及时消除尼日利亚疾病的重要方法。
